The estimated Net Worth of Kenneth Erland Johnson is at least $17.5 Thousand dollars as of 14 February 2020. Dr Johnson owns over 2,410 units of Xeris Biopharma Inc stock worth over $17,489 and over the last 6 years he sold XERS stock worth over $0.
Dr has made over 2 trades of the Xeris Biopharma Inc stock since 2019, according to the Form 4 filled with the SEC. Most recently he bought 2,410 units of XERS stock worth $10,002 on 14 February 2020.
The largest trade he's ever made was buying 2,410 units of Xeris Biopharma Inc stock on 14 February 2020 worth over $10,002. On average, Dr trades about 213 units every 23 days since 2018. As of 14 February 2020 he still owns at least 6,115 units of Xeris Biopharma Inc stock.
You can see the complete history of Dr Johnson stock trades at the bottom of the page.
Dr. Kenneth E. Johnson Pharm. D., Pharm.D. is the Sr. VP of Clinical Devel., Regulatory, Quality Assurance & Medical Affairs at Xeris Biopharma Inc.
Dr D is 58, he's been the Sr. VP of Clinical Devel., Regulatory, and Quality Assurance & Medical Affairs of Xeris Biopharma Inc since . There are 7 older and 11 younger executives at Xeris Biopharma Inc. The oldest executive at Xeris Biopharma Holdings Inc is Jeffrey Sherman, 65, who is the Independent Director.
Kenneth's mailing address filed with the SEC is C/O XERIS BIOPHARMA HOLDINGS, INC., 1375 WEST FULTON STREET, SUITE 1300, CHICAGO, IL, 60607.
Over the last 6 years, insiders at Xeris Biopharma Inc have traded over $2,845,230 worth of Xeris Biopharma Inc stock and bought 2,912,235 units worth $31,442,123 . The most active insiders traders include Group, Llc Green Jeremy Red..., James E Deerfield Mgmt L.P...., and Garheng Kong. On average, Xeris Biopharma Inc executives and independent directors trade stock every 46 days with the average trade being worth of $197,048. The most recent stock trade was executed by John P. Schmid on 12 August 2024, trading 4,515 units of XERS stock currently worth $10,159.
xeris aspires to break through this restraint by developing ultra-low volume, ready-to-use biotherapeutics delivered through patient-friendly injectable devices. products built on our xeriject technologies could potentially ease the pain of injections for hundreds of millions of patients.
Xeris Biopharma Inc executives and other stock owners filed with the SEC include: